Basic Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 14, 2020; 26(22): 3024-3033
Published online Jun 14, 2020. doi: 10.3748/wjg.v26.i22.3024
Table 1 Clinical and pathological details of patients included in the study, n (%)
CharacteristicsPatients (n = 49)
Age (yr): Median61
Sex
Men33 (67.35)
Women16 (32.65)
Tumor size
≤ 5 cm20 (40.8)
5-7 cm17 (34.7)
> 7 cm12 (24.5)
Site of tumor
Upper stomach3 (6.1)
Middle stomach31 (63.3)
Lower stomach15 (30.6)
Type of gastrectomy
Total34 (69.4)
Subtotal15 (30.6)
Pathological tumor stage
T12 (4.1)
T219 (38.7)
T321 (42.9)
T47 (14.3)
Pathological nodal stage
N06 (12.2)
N124 (49)
N215 (30.6)
N34 (8.2)
AJCC stage
IB1 (2)
II14 (28.6)
IIIA15 (30.6)
IIIB5 (10.2)
IV14 (28.6)
Histological type
Differentiated5 (10.2)
Undifferentiated44 (89.8)
Table 2 Evaluation of the detection value of COL10A1 in the diagnosis of gastric cancer patients.
AUCP valueCut-off values (ng/mL)SensitivitySpecificity
GC vs CFC0.9171 (0.8443 to 0.9899)0.0002113.387.76% (75.76%-94.27%)100% (67.56%-100.0%)
Early stage GC vs CFC0.8789 (0.7385 to 1.000)0.003118.181.25% (56.99%-93.41%)100% (67.56%-100.0%)
Advanced stage GC vs CFC1.000 (1.000 to 1.000)0.0001113.3100% (78.47%-100.0%)100% (67.56%-100.0%)
Early stage vs Advanced stage0.7768 (0.5977 to 0.9558)0.0100225.378.57% (52.41%-92.43%)81.25% (56.99%-93.41%)